Yahoo
Tel Aviv - Delayed Quote ILA

Teva Pharmaceutical Industries Limited (TEVA.TA)

12,800.00 +80.00 (+0.63%)
At close: 1:47:43 PM GMT+2
Chart Range Bar
Loading chart for TEVA.TA
  • Previous Close 12,720.00
  • Open 12,810.00
  • Bid --
  • Ask 12,800.00 x 34100
  • Day's Range 12,730.00 - 12,910.00
  • 52 Week Range 6,609.00 - 13,070.00
  • Volume 1,021,023
  • Avg. Volume 1,045,128
  • Market Cap (intraday) 149.285B
  • Beta (5Y Monthly) 0.82
  • PE Ratio (TTM) 67.02
  • EPS (TTM) 1.91
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Nov 28, 2017
  • 1y Target Est --

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

www.tevapharm.com

31,173

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .

YTD Return

TEVA.TA
26.86%
TA-125 (^TA125.TA)
7.70%

1-Year Return

TEVA.TA
94.35%
TA-125 (^TA125.TA)
17.90%

3-Year Return

TEVA.TA
276.69%
TA-125 (^TA125.TA)
137.56%

5-Year Return

TEVA.TA
0.00%
TA-125 (^TA125.TA)
0.00%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 4.14B
Earnings -576M
Profit Margin -13.91%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
1B
2B
3B
4B
-10.0%
-5.0%
0.0%
5.0%
10.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.08%

  • Return on Assets (ttm)

    5.13%

  • Return on Equity (ttm)

    9.69%

  • Revenue (ttm)

    17.32B

  • Net Income Avi to Common (ttm)

    706M

  • Diluted EPS (ttm)

    1.91

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.66B

  • Total Debt/Equity (mrq)

    217.79%

  • Levered Free Cash Flow (ttm)

    2.22B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: